The contributions of this study to the field of ALS were felt more broadly because it demonstrated a dose‐dependent reduction in SOD1 protein levels in the CSF as well as a reduction in the exploratory biomarker: NfL. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.